Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
Summary
This latest close brings the total raised by Therini Bio, in its Series A round first announced in April 2023 to $75 million.This investment builds on Angelini Ventures expertise in neurodegeneration, following its recent investments in Neumirna Therapeutics and Arclight Therapeutics.The funds raised by Therini Bio through its extended Series A financing will enable the company to advance Phase 1b studies evaluating its lead candidate, THN391, a potential first-in-class monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation, for the treatment of Alzheimers Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific.Thomas Thestrup, Ph.D., Senior Principal at Angelini Ventures and deal lead, said We are proud to support Therini Bios mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active investor in companies developing next-generation treatments for neurodegenerative and other CNS disorders, we are excited about Therini Bios first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimers and Diabetic Macular Edema.Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Therini Bios Board of Directors as a Board Observer.Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio, said We are deeply grateful to partner with such a distinguished investor group, both new and old. Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including AD and DME. Angelini Ventures will invest 300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies.To date, Angelini Ventures has invested around 100 million into 18 companies covering a range of therapeutic areas and modalities. Angelini Ventures BioTech portfolio includes Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences.
Funding
Review available funding amount, funding date, investors, and linked company information related to Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases in the interactive ISVWorld profile.